

LIST OF PUBLICATIONS

GERT MAYER

ORIGINAL PAPERS

1. Plattner C, Sallaberger S, Bohn JP, Zavadil C, Keller F, Soleiman A, Tiefenthaler M, **Mayer G**, Pirklbauer M: Rationale and design of the Innsbruck Diabetic Kidney Disease Cohort (IDKDC) – a prospective study investigating etiology and progression of early stage chronic kidney disease in type 2 diabetes. *Clin Kidney J* 2024; 17:sfae 109
2. Leierer J, Salib M, Evgeniou M, Rossignol P, Massy ZA, Kratochwill K, **Mayer G**, Fellström B, Girerd N, Zannad F, Perco P: Identification of endophenotypes supporting outcome prediction in hemodialysis patients based on mechanistic markers of statin treatment. *Heliyon* 2024; in press
3. Halimi JM, **Mayer G** et al. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. *J Hypertens* 2024; 42:
4. Engler F, Kerschbaum J, Keller F, Mayer G: Prevalence, patient burden and physicians' perception of pruritus in hemodialysis patients. *Nephrol Dial Transplant* 2024; 39:277-285
5. Gauckler P, Kesenheimer JS, Leierer J, Kruus M, Schreinlechner M, Theurl F, Bauer A, Denicolò S, Egger A, Seeber B, **Mayer G**, Kolbinger FR, Kronbichler A: Exercise-induced fluid retention, cardiac volume overload, and peripheral edema in ultra-distance cyclists. *Kidney Int Rep* 2024; 9:152-161
6. Panzer M, Meindl E, Schaefer B, Wagner S, Glodny B, **Mayer G**, Pircher A, Schwarz C, Beckmann F, Hejny C, Joachim-Mrosko B, Konzett J, Tilg H, Heidegger I, Wolf M, Weiskirchen R, Zoller H: Intravenous iron induced hypophosphatemia and kidney stone disease. *Bone Rep* 2024; 21:101759
7. Denicolò S, Reinstadler V, Keller F, Thöni S, Eder S, Heerspink HJL, Rosivall L, Wiecek A, Mark PB, Perco P, Leierer J, Kronbichler A, Oberacher H, **Mayer G**: Non-adherence to cardio-metabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus. *Diabetologia* 2024; doi 10.1007/s00125-024-06149-w
8. Campos MAJ, Mavrogeorgis E, Latosinska A, Eder S, Buchwinkler L, Mischak H, Siwy J, Rossing P, **Mayer G**, Jankowski J: Urinary peptide analysis to predict the response to blood pressure medication. *Nephrol Dial Transplant* 2024; 39:873-883
9. Ahluwalia TS, Rönkkö TKE, Eickhoff MK, Curovic VR, Siwy J, Eder S, Denicolò S, **Mayer G**, Mischak H, Rossing P, Persson F: Randomized trial of SGLT2 inhibitor identifies target proteins in diabetic kidney disease. *Kidney Int Rep* 2023; 9:334-346
10. Sourij H, Edlinger R, Prischl F, Kaser S, Horn S, Antlanger M, Paulweber B, Aberer F, Brix J, Cejka D, Stingl H, Kautzky-Willer A, Schmaldienst S, Clodi M, Rosenkranz A, **Mayer G**, Oberbauer R, Saeemann M: Diabetic kidney disease (update 2023) Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology. *Wien Klin Wochenschr* 2023; 135: 182-194
11. Denicolo S, Nair V, Leierer J, Rudnicki M, Kretzler M, **Mayer G**, Ju W, Perco P: Assessment of Fibrinogen-like 2 (FGL2) in human chronic kidney disease through transcriptomic data analysis. *Biomolecules* 2023; 13:89

12. Campos MAJ, Keller F, **Mayer G**, Rossing P, Staessen JA, Delles C, Beige J, Glorieux G, Clark AL, Mullen W, Schanstra JP, Vlahou A, Rossing KPK, Ortiz A, Campbell A, Persson F, Latosinska A, Mischak H, Siwy J, Jankowski J: Prognosis and personalized in silico prediction of treatment efficacy in cardiovascular and chronic kidney disease: A proof-of-concept study. *Pharmaceutical* 2023; 16:1298
13. Canney M, Induruwage D, Tang M, Alencar de Pinho N, Er L, Zhao Y, Djurdjev O, Ahn YH, Behnisch R, Calice-Silva V, Chesnaye NC, de Borst MH, Dember LM, Dionne J, Ebert N, Eder S, Fenton A, Fukagawa M, Furth SL, Hoy WE, Imaizum T, Jager KJ, Jha V, Kang HG, Kitiyakara C, **Mayer G**, Oh KH, Onu U, Pecoits-Filho R, Reichel H, Richards A, Schaefer F, Schaeffner E, Scheppach, JB, Sola L, Ulasi I, Wang J, Yadav AK, Zhang J, Feldman HI, Taal MW, Stengel B, Levin A: Regional variation in hemoglobin distribution among individuals with CKD. *Kidney Int Rep* 2023; 8:2056-2067
14. Gauckler P, Kesenheimer JS, Geetha D, Odler B, Eller K, Laboux T, Alberici F, Zappa M, Chebotareva N, Moiseev S, Bonilla M, Jhaveri KD, Oniszczyk J, Audard V, Costa D, Mastroianni-Kirsztajn G, Bruchfeld A, Muto M, Windpessl M, **Mayer G**, Kronbichler A: COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases. *Frontiers in Immunology* 2023; 14:1228457
15. Gregorich M, Kammer M, Heinzel A, Boeger C, Eckardt KU, Heerspink HLambers. Jung B, **Mayer G**, Meiselbach H, Schmid M, Schultheiss UT, Heinze G, Oberbauer Rainer: Development and validation of a prediction model for future estimated glomerular filtration rate in people with type 2 diabetes and chronic kidney disease. *JAMA Network Open* 2023; 6: e231870
16. Jones RD, Abebe S, Distefano V, **Mayer G**, Poli I, Silvestri C, Slanzi D: Candidate composite biomarker to inform drug treatments for diabetic kidney disease. *Front Med* 2023; 10:1271407
17. Lohia S, Siwy J, Mavrogeorgis E, Eder S, Thoeni S, **Mayer G**, Mischak H, Vlahou A, Jankowski V: Exploratory study analysing the urinary peptidome of T2DM patients suggests changes in ECM but also inflammatory and metabolic pathways following GLP-1R agonist treatment. *Int J Mol Sci* 2023; 24:13540
18. Thöni S, Keller F, Denicolo S, Buchwinkler L, **Mayer G**: Biological variation and reference change value of estimated glomerular filtration rate in humans: a systemic review and meta-analysis. *Front Med* 2023; 48:165-174
19. Thöni S, Keller F, Denicolò S, Eder S, Buchwinkler L, Rosivall L, Wiecek A, Mark PB, Rossing P, Heerspink HL, **Mayer G**: International variability of renal and cardiovascular outcomes and mortality in patients with type 2 diabetes mellitus in Europe. *Kidney Blood Press Res* 2023; 48:165-174
20. Moller AL, Thoeni S, Keller F, Sharifli S, Rasmussen DGK, Genovese F, Karsdal MA, **Mayer G**: Combination therapy of RAS inhibition and SGLT2 inhibitors decreases levels of endotrophin in persons with type 2 diabetes. *Biomedicines* 2023; 11:3084
21. Kraft L., Schanz M, Schrickler S, Ketteler M, **Mayer G**, Rostoker G, Manenti L, Schwenger V, Latus J: The first real-world experience of IV Difelikefalin to treat chronic kidney disease-associated pruritus in haemodialysis patients. *J Eur Acad Dermatol Venero* 2023; doi: 10.1111/jdv.19105
22. Sallaberger S, Buchwinkler L, Eder S, Schneeberger S, **Mayer G**, Pirklbauer M: Population characteristics and clinical outcomes from the renal transplant outcome prediction validation study (TOPVAS). *J Clin Med* 2022; 11:7421
23. Smeijer JD, Koomen JV, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, Kitzman DW, Makino H, **Mayer G**, Nowicki M, Perkovic V, Rossing P, Tobe S, Parving

- HH, de Zeeuw D, Heerspink HJL: Organic anion transporter gene variants associated with plasma exposure and long-term response to Atrasentan in patients with diabetic kidney disease. *Clin Pharmacol Ther* 2022; 112:1098-1107
24. Huber C, Krauss M, Reinstadler V, Denicolo S, **Mayer G**, Schulze T, Brack W, Oberacher H: In silico deconjugation of glucuronide conjugates enhances tandem mass spectra library annotation of human samples. *Anal Bioanal Chem* 2022; 414:2629-2640
 25. Stigler J, Buchwinkler L, Solagna CA, Rudnicki M, Pirklbauer M, **Mayer G**, Kerschbaum J: Humoral immune response to a timely booster mRNA vaccination in non-responders to a standard vaccination schedule against COVID-19 in kidney transplant recipients. *Clin Med* 2022; 11:6439
 26. Ranches G, Zeidler M, Kessler R, Hoelzl M, Hess MW, Vosper J, Perco P, Schramek H, Kummer KK, Kress M, Krogsdam A, Rudnicki M, **Mayer G**, Huettnerhofer A: Exosomal mitochondrial tRNAs and miRNAs as potential predictors of inflammation in renal proximal tubular epithelial cells. *Mol Ther Nucleic Acids* 2022;28:794-813
 27. Denicolo S, Vogl V, Keller F, Thöni S, Eder S, Heerspink HJL, Rosivall L, Wiecek A, Mark PB, Perco P, Leierer J, Kronbichler A, Steger M, Schwendinger S, Zschocke J, **Mayer G**, Jukic E: Clonal hematopoiesis of indeterminate potential and diabetic kidney disease: a nested case control study. *Kidney Int Rep* 2022; 7:876-888
 28. Vogl V, Denicolo S, **Mayer G**, Zschocke J, Jukic E: Response to:"Clonal hematopoiesis of indeterminate potential and diabetic kidney disease: a nested case-control study". *Kidney Int Rep* 2022; 7:2543-2544
 29. Kainz A, Kammer M, Reindl-Schwaighofer R, Strohmaier S, Petr V, Viklicky O, Abramowicz D, Naik M, **Mayer G**, Oberbauer R: Waiting time for second kidney transplantation and mortality. *Clin J Am Soc Nephrol* 2022; 17:90-97
 30. Bakker E, Mol PGM, Nabais J, Vetter T, Kretzler M, Nolan JJ, **Mayer G**, Sundgren AK, Heerspink HJL, Schiel A, de Vries ST, Gomez MF, Schulze F, de Zeeuw D, Pena MJ: Perspectives on a way forward to implementation of precision medicine in patients with diabetic kidney disease: Results of a stakeholder consensus-building meeting. *Front Pharmacol* 2021; 12:662642
 31. Buchwinkler L, Solagna CA, Messner J, Pirklbauer M, Rudnicki M, **Mayer G**, Kerschbaum J: Antibody response to mRNA vaccines against SARS-CoV-2 with chronic kidney disease, hemodialysis, and after kidney transplantation. *J Clin Med* 2021; 11:148
 32. Gregorich M, Heinzl A, Kammer M, Meiselbach H, Böger C, Eckardt KU, **Mayer G**, Heinze G, Oberbauer R: A prediction model for the decline in renal function in people with type 2 diabetes mellitus: study protocol. *Diagn Progn Res* 2021; 5:19
 33. Pirklbauer M, Sallaberger S, Staudinger P, Corazza U, Leierer J, **Mayer G**, Schramek H: Empagliflozin inhibits IL-1 β -mediated inflammatory response in human proximal tubular cells. *Int J Mol Sci* 2021; 22:5089
 34. Garam N, **Mayer G** et al. FHR-5 serum levels and CFHR5 genetic variations in patients with immune complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. *Front Immunol.* 2021; 12:720183
 35. Gauckler P, Bettac EL, Nairz M, Duftner C, Luger AK, Stein M, Wanner D, Böckle BC, Tiefenthaler M, Schratzberger P, Neuwirt H, Harasser L, **Mayer G**, Kronbichler A: What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern. *Ann Rheum Dis* 2021; 80:669-671
 36. Effenberger M, Kronbichler A, Bettac E, Grabherr F, Grandner C, Adolph TE, **Mayer G**, Zoller H, Perco P, Tilg H: Using infodemiology metrics to assess public interest in liver transplantation: Google trends analysis. *J Med Internet Res* 2021; 23:e21656

37. Prischl FC, Rossing P, Bakris G, **Mayer G**, Wanner C: Major adverse renal events (MARE): a proposal to unify renal endpoints. *Nephrol Dial Transplant*. 2021; 36:491-497
38. Leierer J, Perco P, Hofer B, Eder S, Dzien A, Kerschbaum J, Rudnicki M, **Mayer G**: Coregulation analysis of mechanistic biomarkers in autosomal dominant polycystic kidney disease. *Int J Mol Sci* 2021; 22:6885
39. Vlahou A, **Mayer G** et al. Data sharing under the general data protection regulation: time to harmonize law and research ethics? *Hypertension* 2021; 77:1029-1035
40. Beer AGE, Laille E, Neuwirt H, **Mayer G**, Stauder R: Azacitidine is removed effectively by hemodialysis. *Leuk Lymphoma* 2021; 62:743-745
41. Kerschbaum J, Rudnicki M, Dzien A, Dzien-Bischinger C, Winner H, Heerspink HL, Rosivall L, Wiecek A, Mark PB, Eder S, Denicolò S, **Mayer G**: Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers. *Sci Rep*. 2020; 10:19743
42. Pirklbauer M, Bernd M, Fuchs L, Staudinger P, Corazza U, Leierer J, **Mayer G**, Schramek H: Empagliflozin inhibits basal and IL-1 β -mediated MCP-1/CCL2 and endothelin-1 expression in human proximal tubular cells. *Int J Mol Sci* 2020; 21:8189
43. Kerschbaum J, Bitter S, Weitlaner M, Kienzl-Wagner K, Neuwirt H, Bösmüller C, **Mayer G**, Schneeberger S, Rudnicki M: Arterial hypertension as a risk factor for reduced glomerular filtration rate after living kidney donation. *J Clin Med* 2020; 9:338
44. Gauckler P, Leierer J, Kocher F, Feistritz C, Willenbacher W, Gunsilius E, Wolf D, Neuwirt H, **Mayer G**, Kronbichler A: Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma-A case report. *J Clin Apher* 2020; 35:227-230
45. Kronbichler A, Effenberger M, Shin JI, Koppelstätter C, Denicolò S, Rudnicki M, Neuwirt H, Soler MJ, Stevens K, Bruchfeld A, Tilg H, **Mayer G**, Perco P: Is there decreasing public interest in renal transplantation? A Google Trends™ Analysis. *J Clin Med*. 2020; 9:1048
46. Watschinger B, Watschinger C, Reindl-Schwaighofer R, Meyer EL, Deak AT, Hammer T, Eigner M, Sprenger-Mähr H, Schneeberger S, Cejka D, **Mayer G**, Oberbauer R, Rosenkranz AR, Kerschbaum J: Impact of timely public health measures on kidney transplantation in Austria during the SARS-CoV-2 outbreak-a nationwide analysis. *J Clin Med* 2020; 9:3465
47. **Gauckler P**, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, **Mayer G**, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesaf V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R: Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? *Autoimmun Rev* 2020; 19:102671
48. Pirklbauer M, Fuchs L, Heiss R, Ratschiller T, **Mayer G**: Intradialytic calcium kinetics and cardiovascular disease in chronic hemodialysis patients. *Blood Purif* 2020; 49:723-732
49. Effenberger M, Kronbichler A, Shin JI, **Mayer G**, Tilg H, Perco P: Association of the COVID-19 pandemic with Internet Search Volumes: A Google Trends™ Analysis. *Int J Infect Dis* 2020; 95:192-197
50. Gasteiger S, Berchtold V, Bösmüller C, Dostal L, Ulmer H, Bogensperger C, Resch T, Rudnicki M, Neuwirt H, Oberhuber R, Cardini B, Scheidl S, **Mayer G**, Öfner D, Weissenbacher A, Schneeberger S: A retrospective propensity score matched analysis reveals superiority of hypothermic machine perfusion over static cold storage in deceased donor kidney transplantation. *J Clin Med* 2020; 9:2311

51. Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, Collart F, Hemmeler MH, Ambühl P, Kerschbaum J, Legeai C, Del Pino Y, Pino MD, Mircescu G, Mazzoleni L, Hoekstra T, Winzeler R, **Mayer G**, Stel VS, Wanner C, Zoccali C, Massy ZA: Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. *Kidney Int* 2020; 98:1540-1548
52. Garam N, **Mayer G** et al: Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. *Clin Kidney J* 2020; 13:225-234
53. Neuwirt H, Burtscher A, Cherney D, **Mayer G**, Ebenbichler C: Tubulo-glomerular feedback in renal glucosuria: mimicking long-term SGLT-2 inhibitor therapy. *Kidney Med* 2020; 2: 76-79
54. Neuwirt H, **Mayer G**: In Reply to 'Do SGLT-2 inhibitors act only through a functional tubule-glomerular-feedback induced by the increased outflow of sodium? *Kidney Med* 2020; 2: 499
55. **Mayer G**, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI: Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease? reply *Kidney Int* 2020; 97:213-214
56. Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzl A, **Mayer G**: Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. *Diabetologia*. 2019; 62:1154-1166
57. Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, de Zeeuw D, Mark PB, Heinze G, Rossing P, Heerspink HL, **Mayer G**: Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. *Diab Vasc Dis Res* 2019; 16:47-56
58. **Mayer G**, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.: Analysis from the EMPA-REG OUTCOME (R) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. *Kidney Int* 2019; 96:489-504
59. Garam N, **Mayer G** et al: C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. *Orphanet J Rare Dis* 2019; 14:247
60. Perco P, Ju W, Kerschbaum J, Leierer J, Menon R, Zhu C, Kretzler M, **Mayer G**, Rudnicki M: Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease. *JCI Insight* 2019; 4: e128120
61. Kammer M, Heinzl A, Willency JA, Duffin KL, **Mayer G**, Simons K, Gerl MJ, Klose C, Heinze G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, McCarthy MI, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R: Integrative analysis of prognostic biomarkers derived from multi-omics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. *Kidney Int* 2019; 96:1381-1388
62. Weissenbacher A, Oberhuber R, Hermann M, Soleiman A, Ulmer H, **Mayer G**, Margreiter C, Maglione M, Bösmüller C, Messner F, Resch T, Cardini B, Troppmair J, Margreiter R, Öfner D, Schneeberger S: Live confocal tissue assessment with SYTO16/PI and WGA staining visualizes acute organ damage and predicts delayed graft function in kidney transplantation. *Ann Surg* 2019; 270:915-922

63. Garam N, **Mayer G** et al: Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. *Clin Kidney J* 2019; 13:225-234
64. Wagner J, Harrison EM, Martinez Del Pero M, Blane B, **Mayer G**, Leierer J, Gopaluni S, Holmes MA, Parkhill J, Peacock SJ, Jayne DRW, Kronbichler A: The composition and functional protein subsystems of the human nasal microbiome in granulomatosis with polyangiitis: a pilot study. *Microbiome* 2019; 7:137
65. Jordan H, **Mayer G** et al: Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. *J Hypertens* 2019; 37:1541-1546
66. Koppelstaetter C, Leierer J, Rudnicki M, Kerschbaum J, Kronbichler A, Melk A, **Mayer G**, Perco P: Computational drug screening identifies compounds targeting renal age-associated molecular profiles. *Comput Struct Biotechnol J* 2019; 17:843-853
67. Neuwirt H, Leitner-Lechner I, Kerschbaum J, Ertl M, Pöggsteiner F, Pölt N, Mätzler J, Sprenger-Mähr H, Rudnicki M, Schratzberger P, Eder IE, **Mayer G**: Efficacy and safety of Belatacept treatment in renal allograft recipients at high cardiovascular risk - a single center experience. *J Clin Med* 2019; 8:1164
68. Kronbichler A, Leierer J, Shin JI, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Brunetta P, Fervenza FC, Geetha D, Keogh KA, Monach PA, Ytterberg SR, **Mayer G**, Specks U, Stone JH: Association of pulmonary hemorrhage, positive Proteinase 3, and urinary red blood cell casts with venous thromboembolism in antineutrophil cytoplasmic antibody-associated vasculitis. RAVE-ITN Research Group. *Arthritis Rheumatol* 2019; 71:1888-1893
69. Kronbichler A, Gauckler P, Lee KH, Shin JI, Malvezzi P, **Mayer G**: Immunoabsorption in nephrotic syndrome: Where are we now and where are we going from here? *Atheroscler* 2019; 40:55-60
70. Sourij H, Edlinger R, Prischl FC, Auinger M, Kaser S, Horn S, Paulweber B, Kautzky-Willer A, Säemann M, Prager R, Clodi M, Schernthaner G, **Mayer G**, Oberbauer R, Rosenkranz AR: Diabetic kidney disease (Update 2019): Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology. *Wien Klin Wochenschr.* 2019; 131:151-163
71. Weber T, **Mayer G** et al: Austrian Consensus on High Blood Pressure 2019. *Wien Klin Wochenschr* 2019; 131:489-590
72. Pirklbauer M, Schupart R, Fuchs L, Staudinger P, Corazza U, Sallaberger S, Leierer J, **Mayer G**, Schramek H: Unravelling reno-protective effects of SGLT2 inhibition in human proximal tubular cells. *Am J Physiol Renal Physiol* 2019; 316: F449-F462
73. Zewinger S, Rauen T, Rudnicki M, Federico G, Wagner M, Triem S, Schunk SJ, Petrakis I, Schmit D, Wagenpfeil S, Heine GH, **Mayer G**, Floege J, Fliser D, Gröne HJ, Speer T: Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. *J Am Soc Nephrol* 2018; 29:2722-2733
74. Sulzgruber P, Alber H, Altenberger J, Clodi M, Fasching P, Francesconi C, Kautzky-Willer A, **Mayer G**, Podczeck-Schweighofer A, Wapnah L, Drexel H, Koller L, Wascher TC, Huber K, Niessner A: Antidiabetic therapy of patients with cardiovascular disease - a review of current literature and implementation in clinical practice. *J Kardiologie* 2018, 25:124-127
75. Heinzl A, Kammer M, **Mayer G**, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, Gilmour P, Wilson JM, Duffin KL, Abdalla M, McCarthy MI, Heinze G, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R: Validation of plasma

- biomarker candidates for the prediction of eGFR decline in patients with type 2 diabetes. *Diabetes Care* 2018; 41:1947-1954
76. Koppelstaetter C, Kern G, Leierer G, Mair SM, **Mayer G**, Leierer J: Effect of cyclosporine, tacrolimus and sirolimus on cellular senescence in renal epithelial cells. *Toxicol In Vitro* 2018; 48:86-92
 77. Fanciulli A, **Mayer G** et al: Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). *Clin Auton Res* 2018; 28:355-362
 78. Perco P, Heinzl A, Leierer J, Schneeberger S, Bösmüller C, Oberhuber R, Wagner S, Engler F, **Mayer G**: Validation of systems biology derived molecular markers of renal donor organ status associated with long term allograft function. *Sci Rep* 2018; 8:6974
 79. Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, de Zeeuw D, Mark PB, Heinze G, Rossing P, Heerspink HL, **Mayer G**: A prospective cohort study in patients with type 2 diabetes mellitus for validation of biomarkers (PROVALID) - study design and baseline characteristics. *Kidney Blood Press Res* 2018; 43:181-190
 80. Khurana R, Ranches G, Schaffner S, Lukasser M, Rudnicki M, **Mayer G**, Huettenhofer A: Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease. *RNA* 2017; 23:142-152.
 81. Lenninger M, Schweibert N, Leierer J, Weigel G, Loacker L, Neuwirt H, **Mayer G**, Bechtold T: Separation of metabolic products by electroosmotic dialysis in the plasma model. *Electrochimica Acta* 2017; 258:1356-1364.
 82. **Mayer G**, Heerspink HJL, Aschauer C, Heinzl A, Heinze G, Kainz A, Sunzenauer J, Perco P, de Zeeuw D, Rossing P, Pena M, Oberbauer R: Systems biology-derived biomarkers to predict progression of renal function decline in type 2 diabetes. *Diabetes Care* 2017; 40:391-397
 83. Krochmal M, Kontostathi G, Magalhães P, Makridakis M, Klein J, Husi H, Leierer J, **Mayer G**, Bascands JL, Denis C, Zoidakis J, Zürlig P, Delles C, Schanstra JP, Mischak H, Vlahou A: Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. *Sci Rep* 2017; 7:15160
 84. Kronbichler A, Leierer J, Leierer G, **Mayer G**, Casian A, Höglund P, Westman K, Jayne D: Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. *Rheumatology* 2017; 56:704-708
 85. Reinstadler SJ, Kronbichler A, Reindl M, Feistritzer HJ, Innerhofer V, Mayr A, Klug G, Tiefenthaler M, **Mayer G**, Metzler B: Acute kidney injury is associated with microvascular myocardial damage following myocardial infarction. *Kidney Int* 2017; 92:743-750
 86. Ranches G, Lukasser M, Schramek H, Ploner A, Stasyk T, **Mayer G**, Hüttenhofer A: In vitro selection of cell-internalizing DNA aptamers in a model system of inflammatory kidney disease. *Mol Ther Nucleic Acids* 2017; 8:198-210
 87. Kofler M, Lenninger M, **Mayer G**, Neuwirt H, Grimm M, Bechtold T: Multi-chamber electroosmosis using textile reinforced agar membranes - A promising concept for the future of hemodialysis. *Carbohydrates Polymers* 2016; 136:81-86
 88. Kronbichler A, Kerschbaum J, Gründlinger G, Leierer J, **Mayer G**, Rudnicki M: Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. *Nephrol Dial Transplant* 2016; 31:930-936
 89. Dienemann T, Fujii N, Orlandi P, Nessel L, Furth SL, Hoy WE, Matsuo S, **Mayer G**, Methven S, Schaefer F, Schaeffner ES, Sola L, Stengel B, Wanner C, Zhang L, Levin A,

- Eckardt KU, Feldman HI: International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. *BMC Nephrology* 2016; 17:121
90. Leierer J, Rudnicki M, Braniff SJ, Perco P, Koppelstaetter C, Muehlberger I, Eder S, Kerschbaum J, Schwarzer C, Schroll A, Weiss G, Schneeberger S, Wagner S, Koenigsrainer A, Boehmig G, **Mayer G**: Metallothioneins and renal ageing. *Nephrol Dial Transplant* 2016; 31:1444-1452
 91. Pirklbauer M, Schupart R, **Mayer G**: Acute calcium kinetics in haemodialysis patients. *Eur J Clin Invest* 2016; 46:976-984
 92. Sourij H, Edlinger R, Prischl F, Auinger M, Kautzky-Willer A, Saeemann M, Prager R, Clodi M, Schernthaner G, **Mayer G**, Oberbauer R, Rosenkranz AR: Diabetic kidney disease - Update 2016. *Wien Klin Wochenschr* 2016; 128:85-96
 93. Rudnicki M, Perco P, D'haene B, Leierer J, Heinzl A, Muehlberger I, Schweibert N, Sunzenauer J, Regele H, Kronbichler A, Mestdagh P, Vandesompele J, Mayer B, **Mayer G**: Renal microRNA- and RNA-profiles in progressive chronic kidney disease. *Eur J Clin Invest* 2016; 46:213-226.
 94. Heinze G, Wallisch C, Kainz A, Hronsky M, Leffondre K, Oberbauer R, **Mayer G**: Chances and challenges of using routine data collections for renal health care research. *Nephrol Dial Transplant* 2015; 30:68-75
 95. Prischl F, Auinger M, Saeemann M, **Mayer G**, Rosenkranz AR, Wallner M, Kramar R, Austrian Dialysis Transplant Registry: Diabetes-related end-stage renal disease in Austria 1965-2013. *Nephrol Dial Transplant* 2015; 30:1920-1927
 96. Sarközi R, Corazza U, Osterkamp JP, Pirklbauer M, **Mayer G**, Schramek H: Synergistic induction of CCL2/MCP-1 expression driven by oncostatin M and IL-1 β in human proximal tubular cells depends on STAT3 and p65. *Physiol Rep* 2015; 3:e12298
 97. Zoccali C, Amodeo D, Argiles A, Arici M, D'arrigo G, Evenepoel P, Fliser D, Fox J, Gesualdo L, Jadoul M, Ketteler M, Malyszko J, Massy Z, **Mayer G**, Ortiz A, Sever M, Vanholder R, Vinck C, Wanner C, Wiecek A: The fate of triaged and rejected manuscripts. *Nephrol Dial Transplant* 2015; 30:1947-1950
 98. Kronbichler A, Gut N, Zwerina J, Neuwirt H, Rudnicki M, **Mayer G**: Extending the spectrum of a chameleon: IgG4-related disease appearing as interstitial nephritis and mimicking anti-neutrophil cytoplasmic antibody-associated vasculitis. *Rheumatology* 2015; 54:1936-1938
 99. Dickinson H, Lukasser M, **Mayer G**, Hüttenhofer A: Cell-SELEX: in vitro selection of synthetic small specific ligands. *Methods Mol Biol* 2015; 1296:213-24
 100. Neuwirt H, Perco P, Kainz A, Muehlberger I, Leierer J, Braniff SJ, Mayer B, **Mayer G**, Rudnicki M: A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases. *BMC Med Gen* 2014; 7:75
 101. Poelzl G, Trenkler C, Kliebhan J, Wuertinger P, Seger C, Kaser S, **Mayer G**, Pirklbauer M, Ulmer H, Griesmacher A: FGF23 is associated with disease severity and prognosis in chronic heart failure. *Eur J Clin Invest* 2014; 44:1150-1158
 102. **Mayer G**: Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. *J Hypertonie* 2014; 18:72-73
 103. Mochalski P, King J, Haas M, Unterkofler A, Amann A, **Mayer G**: Blood and breath profiles of volatile organic compounds in patients with end stage renal disease. *BMC Nephrol* 2014; 15:43
 104. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, **Mayer G**, Rudnicki M: Rituximab treatment for relapsing

- minimal change disease and focal segmental glomerulosclerosis: a systematic review. *Am J Nephrol* 2014; 39:322-330
105. Welzl K, Kern G, **Mayer G**, Weinberger B, Säemann M, Sturm G, Grubeck-Loebenstein B, Koppelstaetter C: Effect of different immunosuppressive drugs on immune cells from young and old healthy persons. *Gerontology* 2014; 60:229-238
 106. Kern G, Mair SM, Noppert SJ, Jennings P, Schramek H, Rudnicki M, Mueller GA, **Mayer G**, Koppelstaetter C: Tacrolimus increases NOX4 expression in human fibroblasts and induces fibrosis related genes by aberrant TGF-beta receptor signaling. *PLoS One* 2014; 9: e96377
 107. Welzl K, Weinberger B, Kronbichler A, Sturm G, Kern G, **Mayer G**, Grubeck-Loebenstein B, Koppelstaetter C; How immunosuppressive therapy affects T cells from kidney transplanted patients of different age: the role of latent cytomegalovirus infection. *Clin Exp Immunol* 2014; 176:112-119
 108. Kronbichler A, **Mayer G**: Nephrotic syndrome: is Rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis? *J Nephrol* 2014; 3:1-3
 109. Heinzl A, Perco P, **Mayer G**, Oberbauer R, Lukas A, Mayer B: From molecular signatures to predictive biomarkers: modelling disease pathophysiology and drug mechanism of action. *Front Cell Develop Biol* 2014; 2:37
 110. Kronbichler A, König P, Busch M, Wolf D, **Mayer G**, Rudnicki M: Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. *Wien Klin Wochenschr* 2013; 125:328-333
 111. Hellemons ME, Kerschbaum J, Bakker SJ, Neuwirt H, Mayer B, **Mayer G**, de Zeeuw D, Heerspink HL, Rudnicki M: Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic. *Diab Med* 2012; 29:567-577
 112. Sarközi R, Flucher K, Haller VM, Pirklbauer M, **Mayer G**, Schramek H: Oncostatin M inhibits TGF-beta1-induced CTGF expression via STAT3 in human proximal tubular. *Biochem Biophys Res Com* 2012; 424:801-806
 113. Mühlberger I, Mönks K, Fechete R, **Mayer G**, Oberbauer R, Mayer B, Perco P: Molecular pathways and crosstalk characterizing the cardiorenal. *OMICS* 2012; 16:105-112
 114. Weissenbacher A, Jara M, Ulmer H, Biebl M, Bösmüller C, Schneeberger S, **Mayer G**, Pratschke J, Öllinger R: Recipient and donor body mass index as important risk factors for delayed kidney graft. *Transplantation* 2012; 93:524-529
 115. Rudnicki M, Perco P, Neuwirt H, Noppert SJ, Leierer J, Sunzenauer J, Eder S, Zoja CM, Eller K, Rosenkranz AR., Müller GA, Mayer B, **Mayer G**: Increased renal versican expression is associated with progression of chronic kidney disease. *PLoS One* 2012 7:e44891
 116. Zitt E, Woess E, **Mayer G**, Lhotta K: Effect of Cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism. *Transplantation* 2011; 92:883-889
 117. Eller P, Eller K, Kirsch AH, Patsch JJ, Wolf AM, Tagwerker A, Stanzl U, Kaindl R, Kahlenberg R, **Mayer G**, Patsch JR, Rosenkranz AR: A murine model of phosphate nephropathy. *Am J Pathol* 2011; 178:1999-2006
 118. Eller K, Wolf D, Huber JM, Metz M, **Mayer G**, McKenzie AN, Maurer M, Rosenkranz AR, Wolf AM: IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune-suppression. *J Immunol* 2011; 186:83-91

119. Zitt E, Kirsch AH, Haueis M, Strasak A, Neyer U, **Mayer G**, Rosenkranz AR: The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients. *Clin Nephrol* 2011; 75:309-318
120. Fechete R, Heinzl A, Perco P, Mönks K, Söllner J, Stelzer G, Eder S, Lancet D, Oberbauer R, **Mayer G**, Mayer B: Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. *Prot Clin Appl* 2011; 5:354-366
121. Kerschbaum J, König P, Hausdorfer J, **Mayer G**, Rudnicki M: Sevelamer use and incidence of peritonitis in peritoneal dialysis. *Wien Klin Wochenschr* 2011; 123:204-208
122. Neuwirt H, Rudnicki M, Schramek H, **Mayer G**: Monoclonal light chains and the kidney. *Nephrol Rev* 2011; 3:13-22
123. **Mayer G**: The evolution of kidney function. *J Hypertonie*; 15:9-12
124. Mühlberger I, Moenks K, Bernthaler A, Jandrasits C, Mayer B, **Mayer G**, Oberbauer R, Perco P: Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome. *Int J Nephrol* 2011; 809378
125. **Mayer G**, Heinze G, Mischak H, Hellemons ME, Heerspink HJ, Bakker SJ, de Zeeuw D, Haiduk M, Rossing P, Oberbauer R: Omics-bioinformatics in the context of clinical data. *Meth Mol Biol* 2011; 719:479-497
126. Sonnweber T, Theurl I, Seifert M, Schroll A, Eder S, **Mayer G**, Weiss G: Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. *Nephrol Dial Transplantat* 2011; 26:977-987
127. Zitt E, Eller K, Huber JM, Kirsch AH, Tagwerker A, **Mayer G**, Rosenkranz AR: The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomerulonephritis. *Int J Clin Exp Pathol* 2011; 4:606-615
128. Sarközi R, Hauser C, Noppert SJ, Kronbichler A, Pirklbauer M, Haller V, Grillari J, Grillari-Voglauer R, **Mayer G**, Schramek H: Oncostatin M is a novel inhibitor of TGF-beta 1-induced extracellular matrix protein expression. *Am J Physiol Ren Physiol* 2011; 301:F1014-F1025
129. Eller K, Weber T, Pruenster M, Wolf AM, **Mayer G**, Rosenkranz AR, Rot A: CCR7 deficiency exacerbates injury in acute nephritis due to aberrant localization of regulatory T cells. *J Am Soc Nephrol* 2010; 21:42-52
130. Rudnicki M, Kerschbaum J, Hausdorfer J, **Mayer G**, König P: Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin D. *Perit Dialysis Inter* 2010; 30:541-548
131. Eller P, Eller K, Wolf AM, Reinstadler SJ, Tagwerker A, Patsch JR, **Mayer G**, Rosenkranz AR: Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. *Kidney Int* 2010; 77:428-435
132. Perco P, Mühlberger I, **Mayer G**, Oberbauer R, Lukas A, Mayer B: Linking transcriptomic and proteomic data on the level of protein interaction networks. *Electrophoresis* 2010; 31:1780-1789
133. Rudnicki M, Perco P, Enrich J, Eder S, Heining D, Bernthaler A, Wiesinger M, Sarközi R, Noppert SJ, Schramek H, Mayer B, Oberbauer R, **Mayer G**: Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. *Lab Invest* 2009; 89:337-346
134. Heinze G, Oberbauer R, Kainz A, Mitterbauer C, Koppelstaetter C, Hörl WH, **Mayer G**: Calcineurin inhibitor-based immunosuppressive therapy, donor age, and long-term outcome after kidney transplantation. *Transplantation* 2009; 87:1821-1829
135. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, **Mayer G**, McMahon

- AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med* 2009; 360: 1395-1407
136. Schramek H, Sarközi R, Lauterberg C, Kronbichler A, Pirklbauer M, Albrecht R, Noppert SJ, Perco P, Rudnicki M, Strutz FM, **Mayer G**: Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. *Lab Invest* 2009; 89:1304-1316
137. Hohegger K, Rudnicki M, Auinger M, Mark W, Margreiter R, **Mayer G**, Rosenkranz AR: Fever of unknown origin in renal transplant patients with tacrolimus. *Clinical Transplantation* 2009; 23:575-579
138. Schwarz CP, Koppelstaetter C, Amann E, **Mayer G**: Impact of anemia on aortic pulse wave velocity in hemodialysis patients. *Kidney Blood Press Res* 2009; 32:210-216
139. Heidenreich U, **Mayer G**, Herold M, Klotz W, Stempf K, Al-Jazrawi L, Lhotta K: Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis. *Lupus* 2009; 18:1276-1280
140. Huber JM, Tagwerker A, Heininger D, **Mayer G**, Rosenkranz AR, Eller K: The proteasome inhibitor Bortezomib aggravates renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol* 2009; 297: F451-460C
141. Lhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, Würzner R, Zimmerhackl LB, **Mayer G**, Fremeaux-Bacchi V: A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria and hypertension. *Clin J Am Soc Nephrol* 2009; 4:1356-1362
142. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, Kobold U, **Mayer G**: Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. *Eur J Clin Invest* 2009; 39:883-890
143. Joannidis M, Rauchenzauner M, Leiner B, Rosenkranz AR, Ebenbichler CF, Laimer M, Tatarczyk T, Meusburger E, **Mayer G**: Effect of intradialytic parenteral nutrition in patients with malnutrition-inflammation complex syndrome on body weight, inflammation, serum lipids and adipocytokines: results from a pilot study. *Eur J Clin Nut* 2008; 62:789-795
144. Koppelstätter C, Schratzberger G, Perco P, Hofer J, Mark W, Ollinger R, Oberbauer R, Schwarz C, Mitterbauer C, Kainz A, Karkoszka A, Wiecek A, Mayer B, **Mayer G**: Markers of cellular senescence in zero-hour biopsies predict outcome in renal transplantation. Cellular senescence and long-term renal allograft function. *Aging Cell* 2008; 7:491-497
145. Hohegger K, Jansky GL, Soleiman A, Wolf AM, Tagwerker A, Seger C, Griesmacher A, **Mayer G**, Rosenkranz AR: Differential effects of rapamycin in anti-GBM glomerulonephritis. *J Am Soc Nephrol* 2008; 19:1520-1529
146. Eller P, Hohegger K, Feuchtnner GM, Zitt E, Tancevski I, Ritsch A, Kronenberg F, Rosenkranz AR, Patsch JR, **Mayer G**: Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. *Nephrol Dial Transplant* 2008; 23:321-327
147. Sarközi R, Perco P, Hohegger K, Enrich J, Wiesinger M, Pirklbauer M, Eder S, Rudnicki M, Rosenkranz AR, Mayer B, **Mayer G**, Schramek H: Bortezomib-induced survival signals and genes in human proximal tubular cells. *J Pharmacol Exp Ther* 2008; 327:645-656
148. **Mayer G**: Renal bone disease. 2008; 15:26-30

149. Weber T, Eber B, Zweiker R, Horn S, Sock S, Gruener P, Pichler M, Mayer G, Eisserer G, Magometschnigg D, Illyes M: Pulse wave velocity, central blood pressure and augmentation index - "novel" parameters for assessment of end organ damage of the arterial system in hypertension. Pathophysiology, methods, prognostic implications, recommendations. *J Hypertonie* 2008; 12; 7-13.
150. Zitt E, Neyer U, Meusburger E, Tiefenthaler M, Kotanko P, **Mayer G**, Rosenkranz AR: Effect of dialysate temperature and diabetes on autonomic cardiovascular regulation during hemodialysis. *Kid Blood Pres Res* 2008; 31:217-225
151. Rudnicki M, Eder S, Perco P, Enrich J, Scheiber K, Koppelstaetter C, Schratzberger G, Mayer B, Oberbauer R, Meyer TW, **Mayer G**: Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. *Kidney Inter* 2007; 71:325-335
152. Hochegger K, Koppelstätter C, Tagwerker A, Huber JM, Heining D, **Mayer G**, Rosenkranz AR: p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol* 2007; 292:F762-768
153. Sarközi R, Miller B, Pollack V, Feifel E, **Mayer G**, Sorokin A, Schramek H: ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signalling in human proximal tubular cells. *J Cell Physiol* 2007; 211:88-100
154. **Mayer G**: Hypertension in metabolic syndrome: epidemiology, importance, pathogenesis and therapy. *J Hypertonie* 2007; 11:16-21.
155. Hochegger K, Eller P, Huber JM, Bernhard D, **Mayer G**, Zlabinger GJ, Rosenkranz AR: Expression of granzyme A in human polymorphonuclear neutrophils. *Immunology* 2007 121:166-173
156. Hochegger K, Perco P, Enrich J, Mayer B, **Mayer G**, Rosenkranz AR, Rudnicki M: In vitro--transcriptional response of polymorphonuclear leukocytes following contact with different antigens *Eur J Clin Invest* 2007; 37:860-869
157. Jennings P, Koppelstaetter C, Aydin S, Abberger T, Wolf AM, **Mayer G**, Pfaller W: Cyclosporine A induces senescence in renal tubular epithelial cells. *Ame J Physiol Renal Physiol* 2007; 293: F831-838
158. Zitt E, Kollerits B, Neyer U, Mark W, Heining D, **Mayer G**, Kronenberg F, Lhotta K: Cigarette smoking and chronic allograft nephropathy. *Nephrol Dial Transplant* 2007; 22:3034-3039
159. Hochegger K, Schätz T, Eller P, Tagwerker A, Heining D, **Mayer G**, Rosenkranz AR: Role of alpha/beta and gamma/delta T cells in renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol* 2007 ; 293: F741-F747
160. Kainz A, Perco P, Mayer B, Soleiman A, Steininger R, **Mayer G**, Mitterbauer C, Schwarz C, Meyer TW, Oberbauer R: Gene-expression profiles and age of donor kidney biopsies obtained before transplantation distinguish medium term graft function. *Transplantation* 2007; 83:1048-1054
161. Pollack V, Sarközi R, Banki Z, Feifel E, When S, Gstraunthaler G, Stoiber H, **Mayer G**, Montesano R, Strutz F, Schramek H: Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signalling. *Am J Physiology Renal Physiol* 2007; 293: F1714-1726
162. Wolf D, Rumpold H, Koppelstaetter C, Gastl GA, Steurer M, **Mayer G**, Gunsilius E, Tilg H, Wolf AM: Telomere length of in vivo expanded CD4(+)/CD25(+) regulatory T-cells is preserved in cancer patients. *Cancer Immunol Immunother* 2006; 55:1198-1208

163. Perco P, Pleban C, Kainz A, Lukas A, **Mayer G**, Mayer B, Oberbauer R: Protein biomarkers associated with acute renal failure and chronic kidney disease. *Eur J Clin Invest* 2006; 36:753-763
164. Perco P, Rapberger R, Siehs C, Lukas A, Oberbauer R, **Mayer G**, Mayer B: Transforming omics data into context: bioinformatics on genomics and proteomics raw data. *Electrophoresis* 2006; 27:2659-2675
165. **Mayer G**: A salty matter: one more contribution to the debate on the optimum level of salt consumption. *Aktuelle Ernährungsmedizin* 2006; 31:110-114
166. Rothe H, **Mayer G**: Clinical importance of calcium-sensing receptor gene polymorphism Arg-990-Gly in the age of calcimimetic therapy. *Curr Pharmacogen* 2006; 4:153-156
167. Berger N, Guggenbichler S, Steurer W, Margreiter C, **Mayer G**, Kafka R, Mark W, Rosenkranz AR, Margreiter R, Bonatti H: Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. *BMC Inf Dis* 2006; 6:127
168. Müller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, **Mayer G**, Konwalinka G, Heufler C, Tiefenthaler M: The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. *Eur J Immunol* 2005; 35:533-545
169. Lhotta K, Kronenberg F, **Mayer G**: Calculated renal function: benefits and problems of the "Modification of Diet in Renal Disease" (MDRD) formula. *Dtsch Med Wochenschr* 2005; 130:2021-2024
170. Wolf D, Hochegger K, Wolf AM, Rumpold HF, Gastl G, Tilg H, **Mayer G**, Gunsilius E, Rosenkranz AR: CD4⁺ CD25⁺ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. *J Am Soc Nephrol* 2005; 16:1360-1370
171. Mähr N, Neyer U, Prischl F, Kramar R, **Mayer G**, Kronenberg F, Lhotta K: Proteinuria and hemoglobin levels in patients with primary glomerular disease. *Am J Kidney Dis* 2005; 46:424-431
172. Hochegger K, Siebenhaar F, Vielhauer V, Heining D, Mayadas TN, **Mayer G**, Maurer M, Rosenkranz AR: Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. *Eur J Immunol* 2005; 35:3074-3082
173. Koppelstaetter C, Jennings P, Hochegger K, Perco P, Ischia R, Karkoszka H, **Mayer G**: Effect of tissue fixatives on telomere length determination by quantitative PCR. *Mech Ageing Develop* 2005; 126:1331-1333
174. Perco P, Kainz A, **Mayer G**, Lukas A, Oberbauer R, Mayer B: Detection of coregulation in differential gene expression profiles. *Biosystems* 2005; 82:235-247
175. Hauser P, Schwarz C, Mitterbauer C, Regele HM, Mühlbacher F, **Mayer G**, Perco P, Mayer B, Meyer TW, Oberbauer R: Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. *Lab Invest* 2004; 84:353-361
176. Koller H, Steurer W, Mark W, Margreiter R, Lhotta K, **Mayer G**, Rosenkranz AR: Clearance of C4d deposition after successful treatment of acute humoral rejection in follow-up biopsies: a report of three cases. *Transplant Int* 2004; 17:177-181
177. Koller H, Zitt E, Staudacher G, Neyer U, **Mayer G**, Rosenkranz AR: Variable parathyroid hormone (1-84) / carboxyl-terminal PTH ratios detected by 4 novel parathyroid hormone assays. *Clin Nephrol* 2004; 61:337-343
178. Koller H, **Mayer G**: Evaluation of the living kidney donor. *Nephrol Dial Transplant* 2004; 19:41-44
179. Rudnicki M, Eder S, Schratzberger G, Mayer B, Meyer TW, Tonko M, **Mayer G**: Reliability of T7-based mRNA linear amplification validated by gene expression analysis of human kidney cells Using cDNA microarrays. *Nephron Exp Nephro* 2004; 97:e86-e95

180. Tiefenthaler M, Hofer S, Ebner S, Ivarsson L, Neyer S, Herold M, **Mayer G**, Fritsch P, Heufler C: In vitro treatment of dendritic cells with Tacrolimus: impaired T-cell activation and IP-10 expression. *Nephrol Dial Transplant* 2004 ; 19:553-560
181. Hochegger K, Knight S, Hugo C, **Mayer G**, Lawler J, Mayadas TN, Rosenkranz AR: Role of thrombospondin-1 in the autologous phase of an accelerated model of anti-glomerular basement membrane glomerulonephritis. *Nephron Exp Nephrol* 2004; 96:31-38
182. Koller H, Hochegger K, Zlabinger GJ, Lhotta K, **Mayer G**, Rosenkranz AR: Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system. *Nephrol Dial Transplant* 2004; 19:3104-3111
183. Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, **Mayer**, Luger A: Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis. *J Nephrol* 2004, 17:87-94
184. Kainz A, Mitterbauer C, Hauser P, Schwarz C, Regele HM, Berlakovich G, **Mayer G**, Perco P, Mayer B, Meyer TW, Oberbauer R: Alterations in gene expression in cadaveric vs. live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. *Am J Transplant* 2004; 4:1595-1604
185. Joannidis M, Truebsbach S, Bijuklic K, Schratzberger P, Dunzedorfer P, Wintersteiger S, Lhotta K, **Mayer G**, Wiedermann CJ: Neutrophil transmigration in renal proximal tubular LLC-PK1 cells. *Cell Physiol Biochem* 2004; 14:101-112
186. Kotzmann H, Schmidt A, Lercher P, Schuster E, Geyer G, Frisch H, Hörl WH, **Mayer G**, Luger A: One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients. *Nephron Clin Prac* 2003; 93:75-82
187. Hochegger K, **Mayer G**, Rosenkranz AR: Is HIV-infection a contraindication for kidney transplantation? *Nephrol Dial Transplant* 2003; 18:217-218
188. Wamser P, Asari R, Goetzinger G, **Mayer G**, Berlakovich G, Soliman T, Mühlbacher F, Steininger R: Detrimental effects of controlled reperfusion on renal function after porcine autotransplantation are fully compensated by the use of Carolina rinse solution. *Transplant Int* 2003; 16:191-196
189. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, **Mayer G**: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. *Kidney Int* 2003; 64:572-578
190. Wimmer F, Oberaigner W, Kramar R, **Mayer G**: Regional variability in the incidence of end-stage renal disease: an epidemiological approach. *Nephrol Dial Transplant* 2003; 18:1562-1567
191. Lhotta K, Zoebler M, **Mayer G**, Kronenberg F: Late referral defined by renal function: association with morbidity and mortality. *J Nephrol* 2003; 16:855-861
192. Tiefenthaler M, Gritsch B, Zotter K, **Mayer G**: Kostenreduktion des Dialysebeginns durch rechtzeitige Fistelanlage: Untersuchungen der LKF-Daten der inzidenten Patienten von 1999 bis Oktober 2000 am Landeskrankenhaus Innsbruck / Universitätskliniken. *Acta Med Aust* 2003; 30:121-126
193. Schmidt A, Pleiner J, Bayerle-Eder M, Wiesinger GF, Rodler S, Quittan M, **Mayer G**, Wolzt M: Regular physical exercise improves endothelial function in heart transplant recipients. *Clin Transplant* 2002; 16:137-143
194. Schwarz C, Hauser P, Steininger R, Regele H, Heinze G, **Mayer G**, Oberbauer R: Failure of BCL-2 up-regulation in proximal tubular epithelial-cells of donor kidney biopsy

- specimens is associated with apoptosis and delayed graft function. *Lab Invest* 2002; 82:941-948
195. Weidekamm C, Hauser P, Hansmann C, Schwarz C, Klingler H, **Mayer G**, Oberbauer R: Effects of AT1 and AT2 receptor blockade on angiotensin-II-induced apoptosis of human renal proximal tubular epithelial-cells. *Wien Klin Wochenschr* 2002; 114:725-729
 196. Tiefenthaler M, Riedl-Huter C, Roth T, Bodner G, **Mayer G**: Ultrasonic diagnosis of calciphylactic lesions. *Ultraschall Med* 2002; 23:403-406
 197. Haas M, Leko-Mohr Z, Erler C, **Mayer G**: Antiproteinuric versus antihypertensive effects of high-dose ACE-inhibitor therapy. *Am J Kidney Dis* 2002; 40:458-463
 198. Hörl WH, Holzer H, **Mayer G**: Treatment of renal anemia with Darbepoetin alfa - results of an Austrian multicentre study. *Wien Klin Wochenschr* 2002; 114:967-971
 199. Siehs C, Oberbauer R, **Mayer G**, Lukas A, Mayer B: Discrete simulation of regulatory homo-dimerization and hetero-dimerization in the apoptosis effector phase. *Bioinformatics* 2002 18:67-76
 200. Lhotta K, Rumpelt HJ, König P, **Mayer G**, Kronenberg F: Cigarette smoking and chronic allograft nephropathy. *Kidney Int* 2002; 61:648-654
 201. Haas M, **Mayer G**, Wirnsberger G, Holzer H, Ratschek M, Neyer U, Neuweiler J, Kramar R, Schneider B, Breiteneder-Geleff B, Regele HR, Hörl W, Kerjaschki D: Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with Probuco - a pilot-study. *Wien Klin Wochenschr* 2002; 114:143-147
 202. Schmidt A, Pleiner J, Schaller G, Roden M, Dallinger S, **Mayer G**, Schmetterer L, Wolzt M: Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. *Kidney Int* 2002; 61:1788-1793
 203. **Mayer G**: Results from the TIP (Tritace in Proteinuria) intensified monitoring project. *Kidney Blood Pres Res* 2002; 25:80-86
 204. Peherstorfer E, Mayer B, Boehm S, Lukas A, Hauser P, **Mayer G**, Oberbauer R: Effects of microinjection of synthetic BCL-2 domain peptides on apoptosis of renal tubular epithelial-cells. *Am J Physiol Renal Physiol* 2002; 283: F190-196
 205. Oberbauer R, Nenov V, Weidekamm C, Haas M, Szekeres T, **Mayer G**: Reduction in mean glomerular pore size coincides with the development of large shunt pores in patients with diabetic nephropathy. *Exp Nephrol* 2001; 9:49-53
 206. Schmidt A, Stefenelli T, Schuster E, **Mayer G**: Informational contribution of non-invasive screening-tests for coronary artery disease in patients on chronic renal replacement therapy. *Am J Kidney Dis* 2001; 37:56-63
 207. Koller H, **Mayer G**: Nierenersatztherapie beim älteren Patienten. *Wien Klin Wochenschr* 2001; 23:12-20
 208. Koller H, Mayer G: Immunosuppressive therapy and bone metabolism after kidney-transplantation. *Acta Med Austr* 2001; 28:81-85.
 209. Schwarz C, Böhmig GA, Steininger R, **Mayer G**, Oberbauer R: Impaired phosphate handling of renal allografts is aggravated under Rapamycin-based immunosuppression. *Nephrol Dial Transplant* 2001; 16:378-382
 210. Schmidt A, Gruber U, Böhmig G, Koller E, **Mayer G**: The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. *Nephrol Dial Transplant* 2001; 16:1034-1037
 211. **Mayer G**: Cardiac Disease – what is different in patients with renal insufficiency? *J Clin Basic Cardiol* 2001; 4:8

212. Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, **Mayer G**: A comparison of quantitative computed-tomography and dual X-ray absorptiometry for evaluation of bone-mineral density in patients on chronic-hemodialysis. *Am J Kidney Dis* 2001; 37:1247-1252
213. Bergler-Klein J, Pirich C, Laufer G, Grimm M, Regele H, **Mayer G**, Oberbauer R: The long-term effect of simultaneous heart and kidney transplantation on native renal function. *Transplantation* 2001; 71:1597-1600
214. Schwarz C, Regele H, Steininger R, Hansmann C, **Mayer G**, Oberbauer R: The contribution of adhesion molecule expression in donor kidney biopsies to early allograft dysfunction. *Transplantation* 2001; 71:1666-1670
215. Schmidt A, Bayerle-Eder M, Pleiner H, Zeisner C, Wolzt M, **Mayer G**, Schmetterer L: The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin A receptor antagonist in men. *Nitric Oxide* 2001; 5:370-376
216. Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, Kreuz S, Geyer G, Frisch H, Hörl WH, **Mayer G**, Luger A: Differential effects of growth hormone therapy in malnourished hemodialysis patients. *Kidney Int* 2001; 60:1578-1585
217. Oberbauer R, Schwarz C, Regele HM, Hansmann C, Meyer TW, **Mayer G**: Regulation of renal tubular cell apoptosis and proliferation after ischemic injury to a solitary kidney. *J Lab Clin Med* 2001; 138:343-351
218. Rosenkranz AR, Peherstorfer E, Körmöczi GF, Zlabinger GJ, **Mayer G**, Hörl WH, Oberbauer R: Complement dependent acceleration of apoptosis in neutrophils by dialyzer membranes. *Kidney Int* 2001; 59: 216-220
219. Kos T, Moser P, Yilmaz N, **Mayer G**, Pacher R, Hallström S: High-performance liquid chromatographic determination of p-aminohippuric acid and iothalamate in human serum and urine: comparison of two sample preparation methods. *J Chromatography* 2000; 740:81-85
220. Lhotta K, König P, **Mayer G**, Oppermann M: Glomerular cells do not express the C5a receptor in human glomerulonephritis. *Nephrol Dial Transplant* 2000; 15:1888-1889
221. Anvari A, Türel Z, Schmidt A, Yilmaz N, **Mayer G**, Huber K, Gottsauner Wolf M: Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias. *Cardiovasc Res* 1999; 43:879-883
222. Rosenkranz AR, Körmöczi GF, Thalhammer F, Menzel EJ, Hörl WH, **Mayer G**, Zlabinger GJ: Novel C5-dependent mechanism of neutrophil stimulation by bio-incompatible dialyzer membranes. *J Am Soc Nephrol* 1999; 10:128-135
223. Haas M, Kerjaschki D, **Mayer G**: Lipid-lowering therapy in membranous nephropathy. *Kidney Int* 1999; 56:110-114
224. Kletzmayer J, **Mayer G**, Legenstein E, Heinz-Peer G, Leitha T, Hörl WH, Kovarik J: Anemia and carnitine supplementation in hemodialyzed patients. *Kidney Int* 1999; 55: 93-106
225. Oberbauer R, Rohrmoser M, Regele H, Mühlbacher F, **Mayer G**: Apoptosis of tubular epithelial cells in donor kidney biopsies predicts early renal allograft function. *J Am Soc Nephrol* 1999; 10:2006-2013
226. Rabensteiner D, Abrahamian H, Irsigler K, Hermann KM, Kiener HP, **Mayer G**, Kaider A, Prager R: ACE gene polymorphism and proliferative retinopathy in type 1 diabetes - results of a case-control study. *Diabetes Care* 1999; 22:1530-1550
227. Haas M, Yilmaz, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner M, Auinger M, Arias I, Schneider B, **Mayer G**: Angiotensin converting enzyme gene polymorphism

- determines the antiproteinuric and systemic hemodynamic effect of Enalapril in patients with proteinuric renal disease. *Kidney Blood Pres Res* 1998; 21:66-70
228. Kos T, Pacher R, Wimmer A, Bojic A, Hülsmann M, Frey B, **Mayer G**, Yilmaz N, Skvarilova L, Spinar J, Vitovec J, Toman J, Wolosczcuck W, Stanek B: Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. *Wien Klin Wochenschr* 1998; 110:89-95
 229. Haas M, Godfrin Y, Oberbauer R, Yilmaz N, Borchhardt K, Regele H, Druml W, Derfler K, **Mayer G**: Plasma immunoadsorption treatment in patients with primary focal and segmental glomerulosclerosis. *Nephrol Dial Transplant* 1998; 13:2013-2016
 230. Clodi M, Riedl M, Schmaldienst S, Vychytil A, Kotzmann H, Kaide Biegelmayer C, **Mayer G**, Waldhäusl W, Luger A: Adrenal function in patients with chronic renal failure. *Am J Kidney Dis* 1998; 32:52-55
 231. Van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, **Mayer G**, de Zeeuw D: Angiotensin converting enzyme Insertion / Deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. *Kidney Int* 1997; 63:23-26
 232. Clodi M, Kotzmann H, Riedl M, Schmidt A, Barnas U, Mühlbacher F, Mustafa G, Hörl WH, Waldhäusl W, **Mayer G**, Luger A: The long-acting dopamine agonist bromocriptine mesylate as additive immunosuppressive drug after kidney transplantation. *Nephrol Dial Transplant* 1997; 12:748-752
 233. Borchhardt K, Hass M, Yilmaz N, Oberbauer R, Schmidt A, Barnas U, **Mayer G**: Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. *Kidney Int* 1997; 52:1622-1625
 234. van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, **Mayer G**, de Zeeuw D: Genetic determinants of progressive renal disease: impact on therapeutic interventions in non-diabetic renal disease. *Kidney Int* 1997; 52:71-74
 235. Barnas U, Schmidt A, Haas M, Kaider A, Tillawi S, Wamser P, **Mayer G**: Parameters associated with chronic renal transplant failure. *Nephrol Dial Transplant* 1997; 12:82-85
 236. Barnas U, **Mayer G**: Glomerular proteinuria in renal transplant patients: mechanisms and treatment. *Kidney Int* 1997; 52:78-84
 237. Barnas U, Schmidt A, Illievich A, Kiener HP, Rabensteiner D, Kaider A, Prager R, Abrahamian H, Irsigler K, **Mayer G**: Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control. *Diabetologia* 1997; 40:327-331
 238. Schmidt A, Kiener HP, Barnas U, Arias I, Illievich A, Auinger M, Graninger W, Kaider A, **Mayer G**: Angiotensin-converting enzyme polymorphism in patients with terminal renal failure. *J Am Soc Nephrol* 1996; 7:314-317
 239. Pagtalunan ME, Oberbauer R, Haas M, Barlan M, **Mayer G**, Olson JL, Meyer TW: Atubular glomeruli in patients with chronic allograft rejection. *Transplantation* 1996; 61:1166-1171
 240. Oberbauer R, Banyai S, Schmidt A, Kornek G, Scheithauer W, **Mayer G**: Serum tumor markers after renal transplantation. *Transplantation* 1996; 62:1506-1509
 241. Barnas U, Schmidt A, Haas M, Oberbauer R, **Mayer G**: The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. *Nephrol Dial Transplant* 1996; 11:1822-1824
 242. Borchhardt KA, Yilmaz N, Haas M, **Mayer G**: Renal function and glomerular permselectivity late after living related donor transplantation. *Transplantation* 1996; 62:47-51

243. Thalhammer F, Schmaldienst S, Elemenyawati I, Atteneder M, Burgmann H, Hollensteiner U, Georgopoulos G, Graninger W, Putz D, Rosenkranz AR, **Mayer G**, Hörl WH, Breyer S: Multiple dose pharmacokinetics of cefpirome in long term hemodialysis patients treated with high flux membranes. *Clin Pharmacol Therapeutics* 1996 60:645-650
244. Heinz-Peer G, Helbich T, Barnas U, **Mayer G**, Mühlbacher F, Mostbeck GH: Renal cell carcinomas of donor origin in two kidney transplants from a single donor. *Transplantation* 1995; 59:912-913
245. Heinz-Peer G, Schoder M, Rand T, **Mayer G**, Mostbeck GH: Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective study. *Radiology* 1995; 195:667-671
246. Oberbauer R, Haas M, Regele H, Barnas U, Schmidt A, **Mayer G**: Glomerular permselectivity in proteinuric patients after kidney transplantation. *J Clin Invest* 1995; 96:22-29
247. Riedl M, Haas M, Oberbauer R, Gisinger J, Luger A, **Mayer G**: The effects of prolonged substitution of recombinant human growth hormone on renal functional reserve in growth hormone deficient adults. *J Am Soc Nephrol* 1995; 6:1434-1438
248. Geberth S, Stier E, Zeier M, **Mayer G**, Rambašek M, Ritz E: More adverse renal prognosis of autosomal dominant polycystic kidney disease in families with primary hypertension. *J Am Soc Nephrol* 1995; 6:1643-1648
249. Radosaljevic A, Temsch E, Pfeffel F, Hammer J, **Mayer G**, Renner F, Pidlich J, Müller C: Elevated levels of serum carbohydrate deficient transferrin are not specific for alcohol abuse in patients with liver disease. *J Hepatol* 1995; 23:706-711
250. Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe AJ, Clarkson AR, Ponticelli C, Campise M, **Mayer G**, Ganten D, Ritz E: No association of converting enzyme Insertion / Deletion polymorphism with immunoglobulin A glomerulonephritis. *Am J Kidney Dis* 1995; 26:727-731
251. Heinz-Peer G, Oettl C, **Mayer G**, Mostbeck GH: Hypoechoic perirenal fat in renal transplant recipients. *Radiology* 1994; 193:717-720
252. **Mayer G**, Lafayette R, Meyer TW: Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. *Kidney Int* 1993; 43:346-353
253. Lafayette R, **Mayer G**, Meyer TW: The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. *J Am Soc Nephrol* 1993; 3:1892-1899
254. Traindl O, Falger S, Reading S, Banyai M, Liebisch B, Gisinger J, Templ E, **Mayer G**, Kovarik J: The effects of Lisinopril on proteinuria in renal transplant recipients. *Transplantation* 1993; 55:1309-1313
255. Daniels BS, Deen WM, **Mayer G**, Meyer TW, Hostetter TH: Glomerular permeability barrier in the rat: functional assessment by in vitro methods. *J Clin Invest* 1993; 92:929-936
256. Ludvik B, **Mayer G**, Stifter S, Putz D, Barnas U, Graf H: Effects of Dichloroacetate on exercise performance in healthy volunteers. *Pflügers Arch* 1993; 423:251-254
257. Putz D, Barnas U, Luger A, **Mayer G**, Woloszczuk W, Graf H: Biocompatibility of high flux membranes. *Int J Artif Org* 1992; 15:369-373
258. Lafayette RA, **Mayer G**, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. *J Clin Invest* 1992; 90:766-771
259. Stefenelli T, Boszotta A, Kliman JF, **Mayer G**, Graf H: Digital vascular reactivity in patients on hemodialysis treated with human recombinant erythropoietin. *VASA* 1991; 20:70-73

260. **Mayer G**, Cada EM, Watzinger U, Barnas U, Graf H: Hemodynamic effects of partial correction of chronic anemia by recombinant human erythropoietin in patients on dialysis. *Am J Kidney Dis* 1991; 17:286-289
261. Steiner G, Külinger B, **Mayer**, Jie Y, Leibl H, Kovarik J, Woloszczuk: Determination of cyclosporine by a competitive binding assay with cyclophilin. *Clin Chem* 1991; 37:403-410
262. Barnas U, Watzinger U, Peer G, **Mayer G**, Graf H: Subcutaneous versus intravenous administration of human recombinant erythropoietin in patients on chronic hemodialysis. *Nefrologia* 1990; 10:116-120
263. **Mayer G**, Thum J, Cada EM, Stummvoll HK, Graf H: Aerobic and anaerobic capacity of chronic hemodialysis patients under continuous therapy with recombinant human erythropoietin. *Nephron* 1989 51:34-39
264. **Mayer G**, Thum J, Graf H: Anaemia and reduced exercise capacity in patients on chronic haemodialysis. *Clin Sci* 1989; 76:265-268
265. **Mayer G**, Legenstein E, Auer B, Graf H, Lohninger H: L-carnitine substitution in patients on chronic haemodialysis. *Nephron* 1989; 52:295-299
266. **Mayer G**, Watzke H, Schwarz HP, Stanek G, Graf H: Endotoxinaemia and bacterial contamination of dialysate in patients on chronic intermittent haemodialysis. *J Nephrol* 1989; 3:173-176
267. Cada EM, **Mayer G**, Schurawitzki F, Karnel F, Graf H: Percutaneous transluminal angioplasty of failing arteriovenous dialysis fistulae. *Nephrol Dial Transplant* 1989; 4:57-61
268. **Mayer G**, Watschinger B, Popow T, Ulrich W, Graf H, Kovarik J: Cytomegalovirus infection after kidney transplantation using cyclosporin A and low-dose prednisolone immunosuppression. *Nephrol Dial Transplant* 1988; 3:464-468
269. **Mayer G**, Thum J, Woloszczuk W, Graf H: Beta-2 microglobulin in haemodialysis patients. *Am J Nephrol* 1988; 8:280-284
270. **Mayer G**, Thum J, Cada EM, Stummvoll HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment. *Kidney Int* 1988; 34:525-528
271. Pohanka E, Zlabinger GJ, **Mayer G**, Woloszczuk W, Kovarik J, Smolen J, Steffen C: Comparison of serum neopterin levels and spontaneous blastogenesis in monitoring of kidney graft recipients. *Transplant Proc* 1988; 20:110-115
272. Kovarik J, **Mayer G**, Pohanka E, Schwarz M, Traindl O, Graf H, Smolen J: Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. *Transplantation* 1988; 45:402-405
273. Watschinger B, Kühner I, **Mayer G**, Graf H: Ergebnisse der chronischen Hämodialysebehandlung bei Patienten mit diabetischer Nephropathie. *Wien Klin Wochenschr* 1988; 3:78-82
274. Watzke H, **Mayer G**, Schwarz HP, Rotter M, Hirschl A, Graf H: Bacterial contamination of dialysate in dialysis associated endotoxinaemia. *J Hosp Inf* 1988; 13:109-115
275. **Mayer G**, Stefanelli T, Cada EM, Thum J, Stummvoll HK, Graf H: Blood pressure and erythropoietin. *Lancet* 1988; 331:351
276. **Mayer G**, Pohanka E, Kovarik J, stummvoll HK: Cytomegalovirus infetion and immunoglobulin therapy in renal transplant recipients- 1988; 318:1066
277. Fraas M, **Mayer G**, Popovic R, Leithner C: Mechanical ventilation with the esophageal tracheal combitube (ETC) in the intensive care unit. *Arch Emerg Med* 1987; 4:219-225
278. **Mayer G**, Schnack C, Kovarik J, Graf H, Scherthaner G: Insulinpumpentherapie bei chronischer, intermittierender Hämodialyse und nach Nierentransplantation. *Nieren- und Hochdruckkrankheiten* 1987; 16:313-316

279. **Mayer G**, Kovarik J, Pohanka E, Schwarz M, Graf H, Woloszczuk W: Serum Prolactin levels after kidney transplantation. *Transplant Proc* 1987; 19:3724-3726
280. **Mayer G**, Thum J, Woloszczuk W, Graf H: Beta 2 microglobulin and hemodialysis. *Lancet* 1987, 329:925
281. Kovarik J, Woloszczuk W, Schwarz M, Pohanka, **Mayer G**, Stummvoll HK: Serum Gamma Interferon and Neopterin in the immunological monitoring of kidney transplant recipients. *Transplant Proc* 1986; 18:1325-1329
282. Graf H, Stummvoll HK, Kovarik J, Irschik H, **Mayer G**, Pohanka E: Individuelle Dialysevorschreibung durch Urea-Kinetik-Modeling unter Einbeziehung der Ultrafiltration. *Nieren- und Hochdruckkrankheiten* 1986; 15:496-498
283. Pohanka E, Schwarz M, **Mayer G**, Woloszczuk W, Kovarik J, Stummvoll HK: Serum Neopterin after kidney transplantation - a usefult tool for graft monitoring? *EDTA-ERA Proc* 1985; 22:665-671

PUBMED LISTED AUTHORSHIP AS NATIONAL COORDINATOR / WORKSHOP PARTICIPANT

1. Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators: Impact of Finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis. *Ann Intern Med* 2023; 176:1606-1616 (NK)
2. David S, Bode C, Stahl K; EXCHANGE-2 Study group: EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock-a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial. *Trials* 2023;24:277
3. Peters B, Beige J, Siwy J, Rudnicki M, Wendt R, Ortiz A, Sanz AB, Mischak H, Reich HN, Nasic S, Mahmood D, Persson A, Fernström A, Weiner M, Stegmayr B; PerSTIGAN Working Group: Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy. *Nephrol Dial Transplant*. 2023; 38:2826-2834
4. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators: Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY Analysis. *Diabetes Care* 2022; 45:2991-2998 (NK)
5. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study. *Diabetes Care* 2022; 45:888-897 (NK)
6. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators: Cardiovascular events with Finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 2021; 385:2252-2263 (NK)
7. Rudnicki M, Siwy J, Wendt R, Lipphardt M, Koziol MJ, Maixnerova D, Peters B, Kerschbaum J, Leierer J, Neprasova M, Banasik M, Sanz AB, Perez-Gomez MV, Ortiz A, Stegmayr B, Tesar V, Mischak H, Beige J, Reich HN; PERSTIGAN working group: Urine proteomics for prediction of disease progression in patients with IgA nephropathy. *Nephrol Dial Transplant* 2021; 37:42-52
8. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020; 383:2219-2229 (NK)
9. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Design and baseline characteristics of the Finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. *Am J Nephrol* 2019; 50:333-344 (NK)
10. Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic

- V, Tobe S, Yi T, Wiggerson M, de Zeeuw D; SONAR Committees and Investigators: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. *Lancet*. 2019; 393:1937-1947 (N K)
11. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM; Conference Participants. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. *Kidney Int* 2016; 89:28-39
 12. Haag Weber M, Vetter A, Thyroff-Friesinger U, INJ Study Group: Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. *Clin Nephrol* 2009; 72:380-390
 13. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24 month efficacy and safety results from the CONVERT trial. *Transplantation* 2009; 87:233-242

REVIEWS AND EDITORIALS

1. Ksiazek SH, Hu L, Andò S, Pirklbauer M, Säemann MD, Ruotolo C, Zaza G, La Manna G, De Nicola L, **Mayer G**, Provenzano M: Renin-Angiotensin–Aldosterone System: From history to practice of a secular topic. *Int J Mol Sci* 2024; 25: 4035
2. Agarwal R, Burton J, Gallieni M, Kalantar-Zadeh K, **Mayer G**, Pollock C, Szeptietowski JC: Alleviating symptoms in patients undergoing long-term hemodialysis: a focus on chronic kidney disease associated pruritus. *Clin Kidney J* 2023; 16:30-40
3. Säemann M, Cejka D, Schmaldienst S, Rosenkranz AR, **Mayer G**: Value of SGLT-2 inhibitors in the treatment of chronic kidney disease: Clinical and practical implications. *Wien Klin Wochenschr* 2023; 135:97-109
4. Denicolo S, **Mayer G**: Precision of prognosis of renal disease in type 2 diabetes mellitus Has the limit been reached? *Nephrologie* 2023; 18: 147-152
5. Eisenga MF, **Mayer G**, Pirklbauer M, Provenzano M: Personalized medicine in CKD patients. *Front Nephrol* 2023; 3:1270382
6. Fliser D, **Mayer G**: Precision medicine in nephrology. *Nephrologie* 2023; 18:129-130
7. Plattner C, Pirklbauer M, **Mayer G**: Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults. *Exp Opin Pharmacother* 2023; 24: 1747-1752
8. Perco P, **Mayer G**: The kidney-more than just the sum of its cellular parts. *Kidney Int* 2022; 102:1217-1219
9. Thöni S, **Mayer G**: Urinary Dickkopf-3 and kidney injury in patients with chronic pulmonary disease. *Kidney Int* 2021; 100:983-985
10. Denicolò S, Perco P, Thöni S, **Mayer G**: Non adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: A narrative review. *J Diabetes Comp* 2021; 35:107931
11. Gauckler P, **Mayer G** et al: Rituximab in membranous nephropathy. *Kidney Int Rep* 2021; 6:881-893
12. **Mayer G**: Precision medicine in nephrology. *Nephrol Dial Transplant* 2021; 368:1-2
13. Ganz T, Aronoff GR, Gaillard CAJM, Goodnough LT, Macdougall IC, **Mayer G**, Porto G, Winkelmayer WC, Wish JB: Iron administration, infection, and anemia management in CKD: untangling the effects of intravenous iron therapy on immunity and infection risk. *Kidney Med* 2020; 2:341-353
14. Kronbichler A, Shin JI, Lee KH, Nakagomi D, Quintana LF, Busch M, Craven A, Luqmani RA, Merkel PA, **Mayer G**, Jayne DRW, Watts RA: Clinical associations of renal involvement in ANCA-associated vasculitis. *Autoimmun Rev* 2020; 19:102495
15. Wenzel RR, **Mayer G**: Antihypertensive therapy and cancer. *J Hypertonie* 2019; 23: 8-17
16. Neuwirt H, Rudnicki, Schratzberger P, Pirklbauer M, Kronbichler A, **Mayer G**: Immunosuppression after renal transplantation. *Europ Med Oncol* 2019; 12:216-221
17. Perco P, Pena M, Heerspink HJL, **Mayer G**: Multimarker panels in diabetic kidney disease: the way to improved clinical trial design and clinical practice? *Kidney Int Rep* 2019; 4:212-221
18. **Mayer G**: Kurzbericht zur Mitgliederbefragung 2018 der Österreichischen Gesellschaft für Innere Medizin. *Wien Klin Wochenschr* 2019; 131:95-96

19. Gauckler P, Shin JI, **Mayer G**, Kronbichler A: Eosinophilia and kidney disease: more than just an incidental finding? *J Clin Med* 2018; 7:529
20. de Vries JK, Levin A, Loud F, Adler A, **Mayer G**, Pena MJ: Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives. *Diabetes Obes Metab.* 2018; 20(S3):24-29
21. Perco P, **Mayer G**: Endogenous factors and mechanisms of renoprotection and renal repair. *Eur J Clin Invest* 2018; 48:e12914
22. Perco P, **Mayer G**: Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information? *Kidney Int* 2018; 93:308-310
23. Hanna MH, Dalla Gassa A, **Mayer G**, Zaza G, Brophy PD, Gesualdo L, Pesce F: The nephrologist of tomorrow: towards a kidney-omic future. *Pediatr Nephrol* 2017; 32:393-404
24. Kronbichler A, Oh J, Meijers B, **Mayer G**, Shin J: Recent progress in deciphering the etiopathogenesis of primary membranous nephropathy. *Biomed Res Int* 2017; 1936372
25. Hüttenhofer A, **Mayer G**: Circulating miRNAs as biomarkers of kidney disease. *Clin Kidney J* 2017; 10:27-29.
26. Kronbichler A, Neumann I, **Mayer G**: The use of calcineurin inhibitors in the treatment of lupus nephritis. *Nephrol Dial Transplant* 2016; 31:1572-1576
27. **Mayer G**.: Progressive renal diseases. Risk prediction models and predictive biomarkers. *Der Nephrologe* 2016; 11:246-251
28. **Mayer G**: Guideline based medicine and personalized medicine: two incompatible concepts? *J Hypertonie* 2016; 20:11-15
29. Beer A, **Mayer G**, Kronbichler A: Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades. *Biomed Res Int* 2016; 4192578
30. Leierer J, **Mayer G**, Kronbichler A: Primary focal segmental glomerulosclerosis: miRNAs and targeted therapies. *Eur J Clin Invest* 2016; 46:954-56
31. **Mayer G**: Renale Anämie. *Der Nephrologe* 2015; 10:396-398
32. Kronbichler A, Kerschbaum J, **Mayer G**: The influence and role of microbial factors in autoimmune kidney diseases: a systematic review. *J Immunol Res* 2015; 858027
33. Mann JFE, Rossing P, Wiecek A, Rosivall L, Mark P, **Mayer G**: Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs? *Nephrol Dial Transplant* 2015; 30:1-5
34. Heerspink HJL, Oberbauer R, Perco P, Heinzl A, Heinze G, **Mayer G**, Mayer B: Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. *Nephrol Dial Transplant* 2015; 30(S4):105-112
35. Pena MJ, de Zeeuw, D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, **Mayer G**, Rossing P, Heerspink HJL: Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. *Nephrol Dial Transplant* 2015; 30:86-95
36. Kronbichler A, Jayne DRW, **Mayer G**: Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. *Eur J Clin Invest* 2015; 45:346-368
37. **Mayer G**: Chronic kidney disease: who is affected, who is at risk and who cares? *Nephrol Dial Transplant* 2014; 29:937-941
38. Kronbichler A, **Mayer G**: Renal involvement in autoimmune connective tissue diseases. *BMC Med* 2013; 11:95
39. **Mayer G**: Walter Hörl Obituary. *Eur J Clin Invest* 2013, 43:897-898

40. Mayer P, Mayer B, **Mayer, G**: Systems biology building a useful model from multiple markers and profiles. *Nephrol Dial Transplant* 2012; 27:3995-4002
41. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles,C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, **Mayer G**, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH,, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A: Implementation of proteomic biomarkers: making it work. *Eur J Clin Invest* 2012; 42:1027-1036
42. **Mayer G**: Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. *Nephrol Dial Transplant* 2011; 26:1132-7
43. Pirklbauer M, **Mayer G** The exchangeable calcium pool: physiology and pathophysiology in chronic kidney disease. *Nephrol Dial Transplant.* 2011; 26:2438-44
44. Noppert SJ, **Mayer G**: In search for the troponin of the kidney. *Curr Med Chem* 2009; 16:4219-4229
45. Rudnicki M, **Mayer G**: Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. *Pharmacogenomics* 2009; 10:463-476
46. Auinger M, Edlinger R, Prischl F, Kautzky-Willer A, Prager R, **Mayer G**, Roden M: Diabetic Nephropathy - Update 2009 Guidelines of the Austrian Diabetes Society and of the Austrian Society for Nephrology. *Wien Klin Wochenschr* 2009; 121:37-42
47. Schernthaner G, Baumgartner H, Lechleitner M, **Mayer G**, Slany J: Antihypertensive therapy of diabetes mellitus. *Wien Klin Wochenschr* 2009; 121:22-24
48. Koppelstaetter C, Kern G, **Mayer G**: Biomarkers of aging with prognostic and predictive value in non-oncological diseases. *Curr Med Chem* 2009; 16:3469-3475
49. **Mayer G**: Renal function in the elderly and drug dosing. *Gerontology* 2009; 55:417-421
50. Oberbauer R, **Mayer G**: Phases, stages and risk factors-considering new immunosuppressive strategies for renal transplant patients: *Transplant Proc* 2009; 41:1
51. Mayer G: An update on the relationship between the kidney, salt and hypertension. *Wien Med Wochenschr* 2008; 158:365-369
52. Auinger M, Edlinger R, Prischl F, Kautzky-Willer A, Prager R, **Mayer G**, Roden M: Diabetische Nephropathie. Leitlinien der Österreichischen Diabetes Gesellschaft und der Österreichischen Gesellschaft für Nephrologie. *Wien Klin Wochenschr* 2007; 119:35-40
53. Schernthaner G, Baumgartner H, Lechleitner M, **Mayer G**, Slany J: Antihypertensive Therapie bei Diabetes mellitus. *Wien Klin Wochenschr* 2007; 119:20-22
54. Rosenkranz AR, Grobner T, **Mayer G**: Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis. *Wien Klin Wochenschr* 2007; 119:271-275
55. Mayer G: Organ allocation systems and management of the renal transplant waiting list. *Prilozi* 2007; 28:283-90
56. **Mayer G**, Persijn G: Eurotransplant Kidney Allocation system (ETKAS): rationale and implementation. *Nephrol Dial Transplant* 2006; 21:2-3
57. Schratzberger G, **Mayer G**: Primäre Glomerulonephritiden. *Wien Klin Wochenschr* 2006; 118: 57-66

58. **Mayer G**: Medicine based on systematic research eminence based medicine or common sense medicine – What would you prefer? EDTNA-ERCA J 2006; 32:2
59. Schratzberger G, **Mayer G**: Age and renal transplantation: An interim analysis. Nephrol Dial Transplant 2003; 18:471-476
60. **Mayer G**: Remission von chronischen Nierenerkrankungen: Ein realistisches Ziel? Wien Klin Wochenschr 2003; 115:405-406
61. Rudnicki M, **Mayer G**: Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease – pathophysiological considerations. Pharmacogenomics 2003 ; 4:153-162
62. Haas M, **Mayer G**: Antioxidant therapy in glomerular disease. Wien Klin Wochenschr 2003; 114:138-140
63. Schratzberger G, **Mayer G**: Chronic allograft failure - a disease we don't understand and can't cure? Nephrol Dial Transplant 2002; 17:1384-1390
64. **Mayer G**: ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am J Kidney Dis 2002; 40:227-35
65. **Mayer G**: Was macht eigentlich ein Nephrologe? Acta Med Aust 2001; 28:61-65
66. Rosenkranz AR, **Mayer G**: Proteinuria in the transplanted patient. Nephrol Dial Transplant 2000; 15:1290-1292
67. Rosenkranz AR, **Mayer G**: Mechanisms of hypertension after renal transplantation. Curr Opin Urology 2000; 10:81-86
68. Thalhammer-Scherrer R, Wieselthaler G, Knoebel P, Schwarzinger I, Simonitsch I, Mitterbauer G, Berlakovich GA, Mannhalter C, Haas M, **Mayer G**, Mühlbacher F, Wollner E, Klepetko W, Lechner K, Jäger U: Posttransplant acute myeloid leukemia. Leukemia 1999; 13:321-326
69. Schmidt A, **Mayer G**: The diagnostic trash bin of focal and segmental glomerulosclerosis – an effort to provide rational clinical guidelines. Nephrol Dial Transplant 1999; 14:550-552
70. Benz RL, Jadoul M, López Gómez JM, Martins M, **Mayer G**, van Olden RW, Piccoli A, Silverberg DS, Teplan V, Winearls CG: How should anaemia be managed in pre-dialysis patients? Nephrol Dial Transplant 1999; 14:67-75
71. **Mayer G**: Kalziumantagonisten und Hypertonie: Auf der Suche nach der absoluten Gewissheit. Wien Klin Wochenschr 1998; 110:621-624
72. Müller E, **Mayer G**: Überlegungen zur Therapie der renalen Anämie mit rekombinantem humanem Erythropoietin bei Patienten mit chronischer Niereninsuffizienz. Wien Klin Wochenschr 1998; 13:10-13
73. **Mayer G**: Determination of glomerular permselectivity: Is it useful for diagnosis and clinical management of patients with glomerular disease? Kidney Blood Pres Res 1998; 21:267-268
74. **Mayer G**: Imaginäre Briefe an Patienten mit diabetischer Nephropathie oder kommt Übersicht von Übersehen? Wien Klin Wochenschr 1997; 109:654-658
75. Haas M, **Mayer G**: Cyclosporin A-associated hypertension - pathomechanisms and clinical consequences. Nephrol Dial Transplant 1997; 12:395-397
76. **Mayer G**, Hörl WH: Cardiovascular effects of increasing hemoglobin in chronic renal failure. Am J Nephrol 1996; 16:263-267
77. Oberbauer R, **Mayer G**: Proteinuria as a consequence of altered glomerular permselectivity – clinical implications. Clin Nephrol 1996; 46:357-361
78. Rohrmoser M, **Mayer G**: Reactive oxygen species and glomerular injury. Kidney Blood Pres Res 1996; 19:263-269

79. Schmidt A, **Mayer G**: Renale Nebenwirkungen der Angiotensin Converting Enzym Inhibitoren. Acta Med Aust 1996; 146:450-453
80. **Mayer G**: Effekte einer Diuretikatherapie auf den Elektrolyt- und Säure-Basenhaushalt. Acta Med Aust 1996; 146:436-439
81. Barnas U, **Mayer G**: Nephroprotektion durch Hemmung des Renin-Angiotensin-Systems–Wunsch oder Wirklichkeit? Wien Klin Wochenschr 1995; 107:10-14
82. Jelakovic B, **Mayer G**: A renocentric view of essential hypertension: lesson to be learnt from kidney transplantation. Nephrol Dial Transplant 1995; 10:1510-1512
83. **Mayer G**: Antihypertensive Therapie bei Niereninsuffizienz. Acta Med Aust 1995; 22:32-34
84. **Mayer G**: Nicht-Immunologische Mechanismen des Funktionsverlustes von Nierentransplantaten. Mitteilungen der Arbeitsgemeinschaft für Klinische Nephrologie 1995; 24:54-59
85. Watzinger U, Peer G, Barnas U, **Mayer G**, Luger A, Kovarik J, Graf H: Die Bedeutung von Erythropoietin für die Nephrologie. Wien Klin Wochenschr 1990; 5:125-130
86. Peer G, Watzinger U, **Mayer G**, Ludvik B, Graf H: Some unanswered questions in the pathogenesis of hypertension in patients treated with erythropoietin. Nefrologia 1990; 10:144-147
87. Mayer G, Pohanka E, Kovarik J, Stummvoll HK: Cytomegalovirus immune globulin in renal transplant recipients. 1988; 318:1066
88. Graf H, **Mayer G**, Cada EM, Stummvoll HK: Effectivity of recombinant human erythropoietin in the treatment of transfusion dependent anaemia in patients on chronic haemodialysis. Wien Klin Wochenschr 1987; 24:355-359

CASE REPORTS

1. Fabian E, **Mayer G**, Eller K, Pollheimer M, Queissner R, Krejs GJ. A thirty-year old nurse with urine dipstick (+++) positive for protein in her late pregnancy. *Wien Klin Wochenschr* 2024; doi: 10.1007/s00508-023-02316-y
2. Pircher C, Schneeberger S, Boesmueller C, Agaimy A, Zoller H, Bale R, Henninger B, **Mayer G**, Neuwirt H: A rare case of Epstein-Barr virus-associated hepatosplenic smooth muscle tumors after kidney transplantation. *Transpl Infect Dis* 2018; 20: e12860
3. Rudnicki M, Mayr JA, Zschocke J, Antretter H, Regele H, Feichtinger RG, Windpessl M, **Mayer G**, Poelzl G: MELAS syndrome and kidney disease without Fanconi syndrome or proteinuria: a case report. *Am J Kidney Dis* 2016; 68:949-953
4. Koppelstaetter C, Kerschbaum J, Lenzhofer M, Glodny B, Esterhammer R, Frick M, Alber H, **Mayer G**: Distal renal artery stenosis after percutaneous Rrenal Ddenervation leading to renal impairment but normotension. *J Clin Hypertens* 2015; 17:162-164
5. Kronbichler A, Frank R, Kirschfink M, Szilagyi A, Csuka D, Prohaszka Z, Schratzberger P, Lhotta K, **Mayer G**: Efficacy of Eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. *Medicine* 2014; 93: e143
6. Kerschbaum J, **Mayer G**, Maurer A: High-dose antioxidant therapy and steroids might improve the outcome of acute renal failure from intoxication by *Cortinarius rubellus*: report of two cases. *Clin Kidney J* 2012; 5:576-578
7. Neuwirt H, Eller P, Tiefenthaler M, **Mayer G**, Rosenkranz AR: A rare case of milky urine. *Wien Klin Wochenschr* 2010; 122:596-600
8. K. Hochegger, K. Lhotta, **G. Mayer**, M. Czejka, W. Hilbe: Pharmacokinetic analysis of Docetaxel during hemodialysis in a patient with locally advanced non-small cell lung cancer. *Nephrol Dial Transplant* 2007; 22:289-290
9. Koller H, Pechlaner C, Lhotta K, **Mayer G**, Rosenkranz AR: A hidden cause of angina pectoris: when ABG analysis is the only helpful diagnostic tool. *Int J Cardiol* 2006; 109:414-416
10. Koller H, Waldenberger P, **Mayer G**, Rosenkranz AR, Lhotta K: Renovascular hypertension in a patient with systemic lupus erythematosus and secondary antiphospholipid antibody syndrome. *Lupus* 2005; 14:566-568
11. Lhotta K, Wurzner R, Rosenkranz AR, Beer R, Rudisch A, Neumair F, **Mayer G**: Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. *Lupus* 2004; 13:139-141
12. Lhotta K, Wurzner R, Rumpelt HJ, Eder P, **Mayer G**: Membranous nephropathy in a patient with hereditary complete complement C4 deficiency. *Nephrol Dial Transplant* 2004; 19:990-993
13. Lhotta K, Eder P, Rumpelt HJ, **Mayer G**, Würzner R: A patient with complete C4 deficiency and membranous nephropathy: response to intravenous immunoglobulin. *Mol Immunol* 2001; 28:61-65
14. Haas M, Kletzmayer J, Staudinger T, Böhmig G, **Mayer G**, Leko-Mohr Z, Druml W: Hypothyroidism as a cause of tacrolimus intoxication and acute renal failure: a case report. *Wien Klin Wochenschr* 2000; 112:939-941

15. Haas M, Kain R, **Mayer G**, Oberbauer R: Heart transplantation or combined heart/kidney transplantation? Even one biopsy may fool you. *Nephrol Dial Transplant* 1999; 14:1014-1015
16. Böhmig GA, Schmaldienst S, Hörl WH, **Mayer G**: Iatrogenic hypercalcemia, hypokalemia and metabolic alkalosis in a lady with vena cava thrombosis – beware of overzealous diuretic treatment. *Nephrol Dial Transplant* 1999; 14:782-784
17. Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, **Mayer G**, Worel N, Lechner K, Greinix H: Effect of high dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. *Annals Hematol* 1999; 78:189-191
18. Haas M, Oberbauer R, Druml W, Derfler K, Görzer H, Schmied M, **Mayer G**: The patient developing Wallenberg`s syndrome during plasma separation. *Nephrol Dial Transplant* 1998; 13:3261-3262
19. Oberbauer R, Fabrizii V, Druml W, **Mayer G**: Acute acid base disorder during plasma immunadsorption treatment using citrate anticoagulation. *Nephrol Dial Transplant* 1998; 13:1581-1582
20. Haas M, Jäger U, **Mayer G**: Interferon alpha 2 and proteinuria in a patient with focal and segmental glomerulosclerosis. *Lancet* 1997; 349:1147-1148
21. Wagner A, **Mayer G**, Röggl G, Linkesch W: Successful treatment of acute renal failure related to bone marrow transplantation. *Nephrol Dial Transplant* 1995; 10:1255